User profiles for Julius Popp
 | Julius PoppProfessor, University of Zurich Verified email at uzh.ch Cited by 10534 |
[HTML][HTML] High cortisol and the risk of dementia and Alzheimer's disease: a review of the literature
Introduction: Cortisol effects on the brain are exerted through two distinct receptors, inducing
complex and even opposite effects on the cerebral structures implicated in the various …
complex and even opposite effects on the cerebral structures implicated in the various …
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
Blood‐brain barrier breakdown, neuroinflammation, and cognitive decline in older adults
Introduction Blood‐brain barrier (BBB) breakdown is observed in older versus younger adults
and in late‐onset Alzheimer's disease versus age‐matched controls, but its causes and …
and in late‐onset Alzheimer's disease versus age‐matched controls, but its causes and …
Sleep characteristics and cognitive impairment in the general population: the HypnoLaus study
Objective: To assess the association between sleep structure and cognitive impairment in
the general population. Methods: Data stemmed from 580 participants aged >65 years of the …
the general population. Methods: Data stemmed from 580 participants aged >65 years of the …
[HTML][HTML] Inflammatory biomarkers in Alzheimer's disease plasma
…, K Meersmans, JL Molinuevo, G Peyratout, J Popp… - Alzheimer's & …, 2019 - Elsevier
Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy
Grail” of AD research and intensively sought; however, there are no well-established …
Grail” of AD research and intensively sought; however, there are no well-established …
[HTML][HTML] The promise of multi-omics approaches to discover biological alterations with clinical relevance in Alzheimer's disease
Beyond the core features of Alzheimer’s disease (AD) pathology, ie amyloid pathology, tau-related
neurodegeneration and microglia response, multiple other molecular alterations and …
neurodegeneration and microglia response, multiple other molecular alterations and …
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment
…, M Daerr, A Joe, N Striepens, H Kölsch, J Popp… - Neurology, 2012 - AAN Enterprises
Objective: To identify biological evidence for Alzheimer disease (AD) in individuals with
subjective memory impairment (SMI) and unimpaired cognitive performance and to investigate …
subjective memory impairment (SMI) and unimpaired cognitive performance and to investigate …
Validity and reliability of the CAM-ICU Flowsheet to diagnose delirium in surgical ICU patients
PURPOSE: Delirium occurs frequently in critical care but often remains undiagnosed
because delirium monitoring is often dismissed as being too time-consuming. This study …
because delirium monitoring is often dismissed as being too time-consuming. This study …
Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum
Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Background Three small trials suggest that intravenous immunoglobulin can affect biomarkers
and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective …
and symptoms of mild-to-moderate Alzheimer's disease. We tested the safety, effective …
